Advancements in Cardiac Tissue Engineering and Repair

Camila, Torres^*
*Correspondence: Camila, Torres, Department of Regenerative Systems, Andes University of Biotechnology, Santiago, Chile, Email:

Introduction

Cardiovascular diseases represent a leading global health challenge, driving significant research into regenerative medicine and tissue engineering as potential therapeutic solutions. The goal is often to repair or replace damaged heart tissues and vessels, improving patient outcomes and quality of life. The field has evolved to encompass a wide array of strategies, from sophisticated biomaterial designs to advanced cellular therapies and novel bioreactor technologies. These approaches aim to restore lost function, prevent detrimental remodeling, and create functional tissue substitutes. Myocardial tissue engineering has seen significant progress. This area covers biomaterial design, cell sources, and bioreactor technologies. It highlights strategies for generating functional heart muscle constructs for regeneration and disease modeling, discussing current challenges and future directions for the field [1].

Further, advanced biofabrication methods, including 3D printing and bioprinting, are explored for creating functional vascular grafts. This field addresses the challenges of mimicking native vessel complexity and achieving long-term patency, emphasizing innovations in biomaterials and cellularization techniques crucial for clinical translation [2].

A key therapeutic strategy for myocardial infarction involves cardiac patches derived from stem cells. This work reviews different stem cell types, biomaterial scaffolds, and growth factors used to enhance cardiac repair, aiming to improve heart function and reduce detrimental scar formation post-infarction [3].

The application of decellularized extracellular matrix in heart valve tissue engineering is a comprehensive area of study. Researchers discuss the advantages and limitations of various decellularization methods, focusing on their potential for creating functional and biocompatible valve substitutes that avoid calcification and growth limitations [4].

Cardiac extracellular matrix (cECM) hydrogels demonstrate therapeutic potential for repairing damaged myocardium. The work discusses how cECM hydrogels provide a native-like microenvironment, promoting cell survival, angiogenesis, and tissue remodeling, highlighting recent advancements in their preparation and functionalization [5].

Bioreactor systems are designed to improve the maturation and vascularization of engineered cardiac tissues. This field covers various bioreactor designs, mechanical and electrical stimulation strategies, and perfusion techniques, all crucial for developing functional and viable cardiac constructs for therapeutic applications [6].

Moreover, organ-on-a-chip platforms play an emerging role in modeling cardiovascular diseases. These microphysiological systems allow for high-throughput drug screening and personalized medicine by replicating the complex physiological environment and cellular interactions of the heart and vasculature in vitro [7].

A scaffold-free approach to cardiac tissue engineering, utilizing human-induced Pluripotent Stem Cell-derived cardiac spheroids, has been demonstrated. This research explores the self-assembly and maturation of these spheroids into functional cardiac tissues, offering a promising alternative to traditional scaffold-based methods for myocardial regeneration [8].

Recent advancements in tissue engineering and regenerative medicine for treating coronary artery disease are highlighted. This includes strategies such as cell-based therapies, biomaterial scaffolds for vascular repair, and growth factor delivery, emphasizing their potential to restore blood flow and myocardial function in affected patients [9].

Finally, various strategies to enhance vascularization within engineered cardiac tissues are critically examined, recognizing this as a major challenge for creating clinically viable constructs. Research discusses biomaterial design, growth factor delivery, and co-culture systems aimed at promoting robust vessel formation and efficient nutrient and waste exchange [10].

Description

The landscape of cardiovascular tissue engineering is broad and dynamic, encompassing efforts to regenerate or replace various components of the cardiovascular system. Significant strides have been made in myocardial tissue engineering, where the focus is on developing functional heart muscle constructs through biomaterial design, innovative cell sources, and sophisticated bioreactor technologies. These efforts are geared towards both regeneration and advanced disease modeling applications [1]. Concurrently, the creation of functional vascular grafts stands as another critical area. Advanced biofabrication methods, including 3D printing and bioprinting, are instrumental here, though challenges persist in accurately mimicking native vessel complexity and ensuring long-term patency. Progress depends heavily on new biomaterials and cellularization techniques [2]. Beyond major vessels, heart valve tissue engineering also sees active research, particularly with the application of decellularized extracellular matrix (dECM). Researchers explore different decellularization methods, aiming for biocompatible valve substitutes that avoid common issues like calcification and growth limitations [4].

For direct myocardial repair, several strategies are under intense investigation. Stem cell-based cardiac patches represent a promising therapeutic avenue for myocardial infarction. Research evaluates various stem cell types, biomaterial scaffolds, and growth factors, all intended to enhance cardiac repair, improve heart function, and minimize scar formation post-infarction [3]. In a related approach, cardiac extracellular matrix (cECM) hydrogels are being explored for their therapeutic potential in repairing damaged myocardium. These hydrogels offer a native-like microenvironment, effectively promoting cell survival, angiogenesis, and tissue remodeling, with continuous advancements in their preparation and functionalization [5]. Complementing scaffold-based methods, a scaffold-free approach to cardiac tissue engineering has emerged, primarily utilizing human-induced Pluripotent Stem Cell-derived cardiac spheroids. This technique explores the self-assembly and maturation of these spheroids into functional cardiac tissues, providing an alternative to traditional scaffold-reliant methods for myocardial regeneration [8].

Developing functional and viable cardiac constructs necessitates advanced supporting technologies, such as bioreactor systems. These systems are specifically designed to enhance the maturation and vascularization of engineered cardiac tissues. Various bioreactor designs, mechanical and electrical stimulation strategies, and perfusion techniques are crucial for reaching therapeutic viability [6]. A persistent and significant challenge in creating clinically viable engineered cardiac tissues is inadequate vascularization. To overcome this, researchers are actively investigating strategies that include innovative biomaterial design, targeted growth factor delivery, and sophisticated co-culture systems. The aim is to promote robust vessel formation and ensure efficient nutrient and waste exchange within the constructs [10].

Beyond direct tissue replacement, microphysiological systems like organ-on-a-chip platforms are increasingly important. These platforms are reviewed for their emerging role in modeling cardiovascular diseases. By replicating the complex physiological environment and cellular interactions of the heart and vasculature in vitro, they enable high-throughput drug screening and support the development of personalized medicine [7]. More broadly, tissue engineering and regenerative medicine are demonstrating promising applications for complex conditions like coronary artery disease. Strategies here involve cell-based therapies, biomaterial scaffolds for vascular repair, and precise growth factor delivery, all emphasizing their potential to restore blood flow and myocardial function in affected patients [9]. This multifaceted research aims to revolutionize how cardiovascular diseases are understood and treated, moving towards more effective and personalized regenerative solutions.

Conclusion

Significant progress marks the field of myocardial tissue engineering, covering biomaterial design, cell sources, and bioreactor technologies. Researchers are focused on generating functional heart muscle constructs for regeneration and disease modeling. Advanced biofabrication methods, including 3D printing and bioprinting, create functional vascular grafts, grappling with the challenge of mimicking native vessel complexity and achieving long-term patency. Innovation in biomaterials and cellularization techniques is crucial for clinical translation here. Stem cell-based cardiac patches act as a key therapeutic strategy for myocardial infarction, with ongoing work reviewing different stem cell types, biomaterial scaffolds, and growth factors to enhance cardiac repair and reduce scar formation. Decellularized extracellular matrix (dECM) finds use in heart valve tissue engineering. Cardiac extracellular matrix (cECM) hydrogels also show therapeutic potential for myocardial repair, promoting cell survival, angiogenesis, and tissue remodeling. Bioreactor systems are critical for improving the maturation and vascularization of engineered cardiac tissues, with various designs and stimulation strategies being explored. Organ-on-a-chip platforms are emerging for modeling cardiovascular diseases, offering high-throughput drug screening and personalized medicine by replicating complex physiological environments. A scaffold-free approach utilizes human-induced Pluripotent Stem Cell-derived cardiac spheroids, exploring their self-assembly into functional cardiac tissues, providing an alternative for myocardial regeneration. Tissue engineering and regenerative medicine demonstrate advancements for coronary artery disease, covering cell-based therapies, biomaterial scaffolds, and growth factor delivery to restore blood flow. Critically, strategies to enhance vascularization within engineered cardiac tissues, a major challenge for clinical viability, involve biomaterial design, growth factor delivery, and co-culture systems. This collective effort aims to develop viable solutions for cardiovascular repair and regeneration.

Acknowledgement

None

Conflict of Interest

None

References

Wei W, Kaiyuan W, Lingli H. "Myocardial Tissue Engineering: Recent Advances and Future Perspectives".Adv Sci (Weinh) 10 (2023):e2206775.

Indexed at, Google Scholar, Crossref

Elodie VB, Samuel CPBS, Sara B. "Biofabrication Strategies for Vascular Tissue Engineering: Challenges and Opportunities".Adv Mater 34 (2022):e2109673.

Indexed at, Google Scholar, Crossref

Yang Y, Xin Y, Xianglong S. "Current progress in stem cell-based cardiac patch for myocardial infarction repair".Biomaterials 264 (2021):120412.

Indexed at, Google Scholar, Crossref

Andrew JRJ, Jeremy AF, Robert AP. "Decellularized extracellular matrix for heart valve tissue engineering: Past, present, and future".J Biomed Mater Res A 108 (2020):1343-1361.

Indexed at, Google Scholar, Crossref

Yuchao F, Yidan D, Qiushi L. "Cardiac extracellular matrix hydrogels as biomaterials for myocardial repair".Biomaterials 293 (2023):121976.

Indexed at, Google Scholar, Crossref

Julia LVA, David WLHVDP, Laura HH. "Bioreactor-Based Approaches for Maturation and Vascularization of Engineered Cardiac Tissue".Tissue Eng Part B Rev 28 (2022):810-827.

Indexed at, Google Scholar, Crossref

Minjung L, Minseong K, Yeajin S. "Organ-on-a-chip technology for cardiovascular disease modeling".Adv Drug Deliv Rev 171 (2021):159-173.

Indexed at, Google Scholar, Crossref

Junya H, Ryosuke I, Yasushi Y. "Scaffold-free cardiac tissue engineering using human-induced pluripotent stem cell-derived cardiac spheroids".J Thorac Cardiovasc Surg 158 (2019):e81-e89.

Indexed at, Google Scholar, Crossref

Zhenyu Z, Yuting W, Ruohan W. "Emerging applications of tissue engineering and regenerative medicine in coronary artery disease".Stem Cell Res Ther 14 (2023):114.

Indexed at, Google Scholar, Crossref

Sarah CS, Sarah PH, Patrick CHH. "Strategies for improving vascularization in engineered cardiac tissue".Adv Drug Deliv Rev 160 (2020):13-32.

Indexed at, Google Scholar, Crossref